妊娠中期筛查妊娠期糖尿病对妊娠结局的影响:TESGO随机对照试验
该双中心平行随机对照试验在967名单胎孕妇中比较孕18-20周与24-28周普遍筛查GDM对妊娠结局的影响,因中期分析无效而提前终止;主要复合结局两组无显著差异,中期筛查组新生儿低血糖显著更低但GDM孕妇新生儿脂肪含量更高。
要点
- 孕18-20周普遍筛查GDM未改善主要复合妊娠结局。
- 中期筛查组新生儿低血糖发生率显著低于标准筛查组。
- 中期筛查诊断GDM的孕妇其新生儿脂肪含量更高。
核心结论
- 将普遍GDM筛查提前至孕18-20周可能不改善妊娠结局,仅降低新生儿低血糖。
- 经中期筛查诊断GDM的孕妇所生新生儿脂肪含量更高。
研究设计与样本
- 双中心、平行、随机对照试验,计划中期分析,纳入单胎孕妇。
- 意向性分析纳入967名孕妇,比较孕18-20周与24-28周筛查。
- 采用75-g OGTT及IADPSG标准普遍筛查和诊断GDM。
主要发现
- 因中期分析无效而提前终止。
- 主要复合结局两组无显著差异。
- 中期筛查组新生儿低血糖显著更低,GDM孕妇新生儿脂肪含量更高。
- 不良事件率两组相似。
关键数值与推荐
- 主要复合结局包括初次剖宫产、出生体重>90百分位、新生儿低血糖、脐血清C肽>90百分位、妊娠期高血压、子痫前期和产伤。
- GDM筛查采用75-g OGTT和IADPSG标准。
临床怎么用
- 现有证据不支持将普遍GDM筛查常规提前至孕18-20周以改善妊娠结局。
- 中期筛查可降低新生儿低血糖,但需注意GDM孕妇新生儿脂肪含量更高。
局限性
- 试验因无效提前终止,可能影响统计效能。
- 仅纳入单胎孕妇,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Newborns delivered by women with gestational diabetes mellitus (GDM) have accelerated intrauterine growth earlier than the current recommended screening period. We aimed to determine whether universal GDM screening using a single oral glucose intolerance test (OGTT) at 18-20 weeks' gestation improves pregnancy outcomes compared with standard screening at 24-28 weeks' gestation. RESEARCH DESIGN AND METHODS: We conducted a dual-center, parallel, randomized controlled trial with a planned interim analysis in singleton pregnant women to compare the effect of midpregnancy screening for GDM at 18-20 weeks' gestation and standard screening at 24-28 weeks' gestation. GDM was universally screened and diagnosed using 75-g OGTTs and the International Association of the Diabetes and Pregnancy Study Groups criteria. The primary outcome was a composite measure of primary cesarean delivery, birth weight >90th percentile, neonatal hypoglycemia, cord serum C-peptide >90th percentile, gestational hypertension, preeclampsia, and birth trauma. RESULTS: The trial was stopped early for futility after the interim analysis. Of the 967 women included in the intention-to-treat analysis, the primary outcome was not significantly different between the two groups. Neonatal hypoglycemia was significantly lower and neonatal adiposity in women with GDM was higher in the midpregnancy screening group compared with the standard screening group. Adverse event rates were similar between the two groups. CONCLUSIONS: Advancing universal GDM screening to midpregnancy at 18-20 weeks' gestation may not improve pregnancy outcomes, except for a reduction in neonatal hypoglycemia. Newborns of women diagnosed with GDM through midpregnancy screening had higher neonatal adiposity.
引用
- Kuo CH, Lin MW, Chen SC, et al. The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial. Diabetes Care. 2026. PMID: 40986699. doi:10.2337/dc25-0084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。